Search research articles
Contact Us
Filters
Showing results (11-20 of 61) with videos related to
Page
of 7
Sort By:
Journal of Medical Economics
|
April 19, 2021
Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial
Elizabeth A Magnuson, Haiyan Li, Katherine Vilain, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
June 11, 2016
Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
Jeffrey D Miller, Xin Ye, Gregory M Lenhart, et al.
Applied Health Economics and Health Policy
|
July 3, 2019
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
Richard F Pollock, William J Valentine, Steven P Marso, et al.
JAMA Cardiology
|
September 30, 2020
Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis
Suzanne V Arnold, Khaja M Chinnakondepalli, Elizabeth A Magnuson, et al.
Journal of Medical Economics
|
November 10, 2011
Cost-effectiveness of prasugrel in a US managed care population
Josephine A Mauskopf, Jonathan B Graham, Jay P Bae, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
October 14, 2024
Quality of Life Effects of Renal Artery Stenting Versus Medical Therapy for Atherosclerotic Renal-Artery Stenosis: Results from the Randomized CORAL Trial
Suzanne V Arnold, Kaijun Wang, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions
|
April 22, 2017
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial
Suzanne J Baron, Yang Lei, Khaja Chinnakondepalli, et al.
American Heart Journal
|
December 19, 2015
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial
Elizabeth A Magnuson, Katherine Vilain, Kaijun Wang, et al.
Circulation. Cardiovascular Quality and Outcomes
|
November 5, 2020
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial
Katherine Vilain, Haiyan Li, Wingham J Kwong, et al.
The American Journal of Cardiology
|
June 2, 2012
Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial)
Amit P Amin, Matthew R Reynolds, Yang Lei, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 61) with videos related to
Sort By:
Page
of 7
Journal of Medical Economics
|
April 19, 2021
Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial
Elizabeth A Magnuson, Haiyan Li, Katherine Vilain, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
June 11, 2016
Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
Jeffrey D Miller, Xin Ye, Gregory M Lenhart, et al.
Applied Health Economics and Health Policy
|
July 3, 2019
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
Richard F Pollock, William J Valentine, Steven P Marso, et al.
JAMA Cardiology
|
September 30, 2020
Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis
Suzanne V Arnold, Khaja M Chinnakondepalli, Elizabeth A Magnuson, et al.
Journal of Medical Economics
|
November 10, 2011
Cost-effectiveness of prasugrel in a US managed care population
Josephine A Mauskopf, Jonathan B Graham, Jay P Bae, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
October 14, 2024
Quality of Life Effects of Renal Artery Stenting Versus Medical Therapy for Atherosclerotic Renal-Artery Stenosis: Results from the Randomized CORAL Trial
Suzanne V Arnold, Kaijun Wang, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions
|
April 22, 2017
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial
Suzanne J Baron, Yang Lei, Khaja Chinnakondepalli, et al.
American Heart Journal
|
December 19, 2015
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial
Elizabeth A Magnuson, Katherine Vilain, Kaijun Wang, et al.
Circulation. Cardiovascular Quality and Outcomes
|
November 5, 2020
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial
Katherine Vilain, Haiyan Li, Wingham J Kwong, et al.
The American Journal of Cardiology
|
June 2, 2012
Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial)
Amit P Amin, Matthew R Reynolds, Yang Lei, et al.
Page
of 7